Engineering Stem Cells to Treat Glioma
Author Information
Author(s): Li Man, Lu Lisen, Xiao Qungen, Maalim Ali Abdi, Nie Bin, Liu Yanchao, Kahlert Ulf D., Shu Kai, Lei Ting, Zhu Mingxin
Primary Institution: Tongji Medical College, Huazhong University of Science and Technology
Hypothesis
Can engineered mesenchymal stem cells (MSCs) expressing IL-12 and nCD47-SLAMF7 effectively reverse the immunosuppressive microenvironment of glioma?
Conclusion
The engineered MSCs significantly inhibited glioma growth and improved survival rates in mouse models.
Supporting Evidence
- Engineered MSCs were shown to effectively home to tumor sites.
- IL-12 and nCD47-SLAMF7 enhanced macrophage phagocytosis of tumor cells.
- Combined treatment with both engineered MSC types significantly improved survival rates in mice.
- High levels of pro-inflammatory cytokines were released in the tumor microenvironment.
- Macrophage polarization towards M1 type was achieved with IL-12 treatment.
Takeaway
Scientists created special stem cells that can help fight brain tumors by changing the environment around the tumor to make it easier for the body's immune system to attack.
Methodology
The study involved engineering MSCs to express IL-12 and nCD47-SLAMF7, followed by in situ injection into glioma sites in mouse models to assess tumor growth inhibition and immune response.
Potential Biases
Potential bias in the selection of mouse models and the interpretation of results.
Limitations
The study primarily focused on mouse models, which may not fully replicate human responses.
Participant Demographics
C57BL/6J female mice were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website